Campaign News
Why we want to see NHS clinical nurse specialists supporting more people with secondary breast cancer
Clinical nurse specialists (CNSs) are vital in supporting patients with a breast cancer diagnosis. For people with secondary (metastatic) br...
Overview of Secondary Breast Cancer in Wales, Summer 2024
Over the last year, we’ve been working hard to address the challenges facing secondary breast cancer patients in Wales.
Joint letter to NICE board ahead of their September meeting
A letter to the NICE board ahead of their September meeting
Year 1 of Scotland's Cancer Action Plan
Read how we plan to progress the actions of the Scottish Cancer Action Plan 2023-2026 and our concerns around the commitment to collect seco...
Missed targets and longer waits - the ‘new normal’ for breast cancer waiting times
In this blog, we review the three years of data now available since NHS England (NHSE) first introduced the faster diagnosis standard (FDS)....
Uncovering and addressing ethnic inequities in breast cancer diagnosis
As Ethnic Minority Cancer Awareness Month draws to a close, we explore new data on how rates of early diagnosis vary between ethnic groups i...
People, partnerships and pathways – improving breast cancer services in Northern Ireland
Over the last year, we’ve been trying to better understand breast cancer in Northern Ireland. We’ve engaged with people affected by breast c...
Delivering a more ambitious screening programme in Scotland
On May 14th, Public Health Scotland published data on how the Scottish Breast Screening Programme performed from 2022 to 2023. In this post,...
Delivering a more ambitious screening programme in Wales
Breast Cancer Now has joined the Breast Screening Programme Board in Wales as a charity partner of Breast Test Wales. We’re working together...
No Time To Waste: how we’re doing so far
Back in January, we launched the next stage of our No Time To Waste campaign. We’re campaigning for a national breast screening awareness ca...
New drugs approved in 2023 and what’s coming up in 2024
Making sure that new and effective breast cancer drugs quickly reach patients on the NHS is a key priority for us. It's important that they’...
Making sure that Enhertu is approved for NHS use in England
Enhertu (also known as trastuzumab deruxtecan) is an exciting new drug for certain people with HER2-low, secondary breast cancer. It’s the f...
Delivering a fair and equal breast screening programme
Breast screening is a powerful tool in diagnosing breast cancer early, but too many people face barriers to taking up their screening invite...
Why we need a national breast screening awareness campaign
Today, we launched the next stage of our No Time To Waste campaign. We’re calling for a national awareness campaign about breast screening a...
Progress of the National Audit of Metastatic (secondary) Breast Cancer
Back in May 2021, the announcement of a new, National Audit of Metastatic (secondary) Breast Cancer (NAoMe) marked a landmark moment. It fol...
Decoding the data on breast cancer waiting times
October 2023 saw changes to the way cancer waiting times are measured in England. We look at how this has impacted people with possible sign...
Clearing the path to secondary breast cancer diagnosis in England
People with secondary breast cancer often tell us about difficulties getting diagnosed quickly. We hear of people having to visit their GP s...
Behind the headlines: anastrozole licensed as a risk-reducing treatment
Following the news that anastrozole is now licensed as a risk-reducing treatment, we look at why using repurposed drugs isn’t always easy, a...
What does the NHS Long Term Workforce Plan mean for breast cancer
Last month, the long-awaited NHS Long Term Workforce Plan for England was published. In this blog we discuss what the plan says and what it ...